Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Cotargeting of PIM, PI3K and Mtor in Mantle Cell Lymphoma (MCL)

Bianca Freysoldt, Andrea Schnaiter, MD, Luca Fischer, Michael O'Neill, PhD, Yvonne Zimmermann, Grit Hutter, Wolfgang Hiddemann, MD, Martin H. Dreyling, MD PhD

Blood (2015) 126 (23): 5120.

https://doi.org/10.1182/blood.V126.23.5120.5120

Published: 2015

Journal Articles

The Novel CDK4/6-Inhibitor Abemaciclib Induces Early G1-Arrest in MCL Cell Lines, Sensitizes Cells to Cytarabine Treatment and Is Additive with Ibrutinib

Luca Fischer, Andrea Schnaiter, MD, Bianca Freysoldt, Markus Irger, Yvonne Zimmermann, Grit Hutter, Wolfgang Hiddemann, MD, Martin H. Dreyling, MD PhD

Blood (2015) 126 (23): 5124.

https://doi.org/10.1182/blood.V126.23.5124.5124

Published: 2015

Journal Articles

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Blood (2014) 123 (21): 3247–3254.

https://doi.org/10.1182/blood-2014-01-546150

Published: 2014

Includes: Supplemental data

Journal Articles

Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial

Billy Michael Chelliah Jebaraj, PhD, Raymonde Busch, PhD, Thorsten Zenz, MD, Andreas Bühler, MD, Dirk Winkler, MD, Andrea Schnaiter, MD, Jennifer Edelmann, MD, Daniel Mertens, PhD, Sebastian Böttcher, MD, Michael Kneba, MD, Ulrich Jäger, MD, Michael K Wenger, MD, Guenter Fingerle-Rowson, MD PhD, Clemens Wendtner, MD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 671.

https://doi.org/10.1182/blood.V122.21.671.671

Published: 2013

Journal Articles

NOTCH1 , SF3B1 , and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG

Andrea Schnaiter, Peter Paschka, Marianna Rossi, Thorsten Zenz, Andreas Bühler, Dirk Winkler, Mario Cazzola, Konstanze Döhner, Jennifer Edelmann, Daniel Mertens, Sabrina Kless, Silja Mack, Raymonde Busch, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer

Blood (2013) 122 (7): 1266–1270.

https://doi.org/10.1182/blood-2013-03-488197

Published: 2013

Includes: Supplemental data

Journal Articles

TP53 , SF3B1 , and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

Blood (2013) 121 (16): 3284–3288.

https://doi.org/10.1182/blood-2012-11-469627

Published: 2013

Includes: Supplemental data

Journal Articles

SF3B1 , NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial

Peter Dreger, MD, Andrea Schnaiter, MD, Marianna Rossi, Peter Paschka, Andreas Bühler, MD, Thorsten Zenz, MD, Sascha Dietrich, MD, Sebastian Böttcher, MD, Donald Bunjes, Michael Stadler, MD, Lutz Uharek, MD, Christof Scheid, MD, PhD, Ute Hegenbart, MD, Michael Hallek, MD, Michael Kneba, MD, PhD, Norbert Schmitz, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2012) 120 (21): 966.

https://doi.org/10.1182/blood.V120.21.966.966

Published: 2012

Journal Articles

NOTCH1, SF3B1 and TP53 Mutations in Fludarabine-Refractory CLL Patients Treated with Alemtuzumab: Results From the CLL2H Trial of the Gcllsg

Andrea Schnaiter, MD, Marianna Rossi, Peter Paschka, Mario Cazzola, Konstanze Döhner, MD, Jennifer Edelmann, MD, Andreas Bühler, MD, Sabrina Kless, Daniel Mertens, PhD, Raymonde Busch, Silja Mack, MSc, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2012) 120 (21): 710.

https://doi.org/10.1182/blood.V120.21.710.710

Published: 2012

Journal Articles

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Blood (2012) 120 (21): 433.

https://doi.org/10.1182/blood.V120.21.433.433

Published: 2012

Journal Articles

Exceptional In Vitro Activity of CD37 Antibodies In CLL

Thorsten Zenz, MD, Matthias Volden, Theresa Mast, Karsten Nordhausen, Dirk Winkler, MD, Andrea Schnaiter, MD, Andreas Buehler, MD, Karl-Heinz Heider, PhD, Volker Reichardt, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2010) 116 (21): 2460.

https://doi.org/10.1182/blood.V116.21.2460.2460

Published: 2010

Journal Articles

In Vitro Activity of the Type II Anti-CD20 Antibody GA101 in Refractory, Genetic High-Risk CLL.

Thorsten Zenz, Matthias Volden, Theresa Mast, Antonio Sarno, Dirk Winkler, Andrea Schnaiter, Andreas Bühler, Christian Klein, Pablo Umana, Hartmut Döhner, Stephan Stilgenbauer

Blood (2009) 114 (22): 2379.

https://doi.org/10.1182/blood.V114.22.2379.2379

Published: 2009

Journal Articles

In-Vitro Effect of the Small Molecule Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Chronic Lymphocytic Leukemia (CLL).

Thorsten Zenz, Antonio Sarno, Andrea Schnaiter, Dirk Winkler, Andreas Bühler, Matthias Volden, Connie L. Erickson-Miller, Yasser Mostafa Kamel, Hartmut Döhner, Stephan Stilgenbauer

Blood (2009) 114 (22): 4408.

https://doi.org/10.1182/blood.V114.22.4408.4408

Published: 2009

Journal Articles

A Novel Paradigm to Trigger Apoptosis in Chronic Lymphocytic Leukemia.

Sandra Loeder, Thorsten Zenz, Andrea Schnaiter, Daniel Mertens, Dirk Winkler, Hartmut Döhner, Klaus-Michael Debatin, MD, Stephan Stilgenbauer, Simone Fulda

Blood (2009) 114 (22): 731.

https://doi.org/10.1182/blood.V114.22.731.731

Published: 2009

NARROW

Cotargeting of PIM, PI3K and Mtor in Mantle Cell Lymphoma (MCL)

The Novel CDK4/6-Inhibitor Abemaciclib Induces Early G1-Arrest in MCL Cell Lines, Sensitizes Cells to Cytarabine Treatment and Is Additive with Ibrutinib

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial

NOTCH1 , SF3B1 , and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG

TP53 , SF3B1 , and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

SF3B1 , NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial

NOTCH1, SF3B1 and TP53 Mutations in Fludarabine-Refractory CLL Patients Treated with Alemtuzumab: Results From the CLL2H Trial of the Gcllsg

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Exceptional In Vitro Activity of CD37 Antibodies In CLL

In Vitro Activity of the Type II Anti-CD20 Antibody GA101 in Refractory, Genetic High-Risk CLL.

In-Vitro Effect of the Small Molecule Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Chronic Lymphocytic Leukemia (CLL).

A Novel Paradigm to Trigger Apoptosis in Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only